{"id":691061,"date":"2024-03-11T18:14:02","date_gmt":"2024-03-11T18:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=691061"},"modified":"2024-03-11T18:14:02","modified_gmt":"2024-03-11T18:14:02","slug":"the-schizophrenia-market-size-is-a-direct-consequence-of-the-increasing-prevalence-of-schizophrenia-among-the-7mm-countries","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-schizophrenia-market-size-is-a-direct-consequence-of-the-increasing-prevalence-of-schizophrenia-among-the-7mm-countries_691061.html","title":{"rendered":"The Schizophrenia Market Size is a direct consequence of the increasing prevalence of schizophrenia among the 7MM countries."},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1710151674.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The Schizophrenia Market Size is a direct consequence of the increasing prevalence of schizophrenia among the 7MM countries.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1710151674.png\" alt=\"The Schizophrenia Market Size is a direct consequence of the increasing prevalence of schizophrenia among the 7MM countries.\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;Schizophrenia Market Insights&nbsp;report includes a comprehensive understanding of current treatment practices, schizophrenia emerging drugs, market share of individual therapies, and current and forecasted schizophrenia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Schizophrenia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight&rsquo;s analysis, the schizophrenia market size was found to be&nbsp;USD 8.6 billion&nbsp;in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.<\/li>\n<li>As per DelveInsight estimates, in the year 2021, the total prevalent cases of Schizophrenia were&nbsp;~6.2 million&nbsp;cases in the 7MM. In the 7MM, the highest number of prevalent cases of schizophrenia were observed in the US.<\/li>\n<li>Leading schizophrenia companies such as&nbsp;Otsuka Pharmaceutical Development &amp; Commercialization, Inc., H. Lundbeck A\/S, Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Merck, SyneuRx International (Taiwan) Corp, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Minerva Neurosciences, BioXcel Therapeutics Inc, Teva Branded Pharmaceutical Products R&amp;D, Inc., Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics,&nbsp;and others are developing novel schizophrenia drugs that can be available in the schizophrenia market in the coming years.<\/li>\n<li>Some of the key therapies for schizophrenia treatment include&nbsp;Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844\/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509\/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231),&nbsp;and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover which therapies are expected to grab the major schizophrenia market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Schizophrenia Market Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Schizophrenia is a serious mental disorder that significantly impairs a person&rsquo;s cognitive functions, emotional regulation, decision-making abilities, and interpersonal relationships. Its origins are multifaceted, arising from a complex interplay of genetic and environmental factors. Individuals with a family history of psychosis are at a higher risk of developing schizophrenia. Symptoms of schizophrenia can vary from person to person and typically fall into three primary categories: psychotic, negative, and cognitive.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Schizophrenia Prevalent Cases<\/li>\n<li>Total Schizophrenia Diagnosed Cases<\/li>\n<li>Schizophrenia Gender-specific Cases<\/li>\n<li>Schizophrenia Severity-specific Cases<\/li>\n<li>Schizophrenia Age-specific Treated Cases<\/li>\n<li>Schizophrenia Treated Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving schizophrenia epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Schizophrenia Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">While there is no cure for schizophrenia, the primary objectives of treatment revolve around alleviating symptoms and preventing relapses. Schizophrenia necessitates ongoing treatment, even after symptom remission. A combination of medications and psychosocial therapy is typically employed to effectively manage the condition. In severe cases, hospitalization may be required. The pharmacological approach plays a pivotal role in treating schizophrenia, offering a range of mono and combination therapies. Antipsychotic medications are the foremost choice among psychotropic agents for schizophrenia treatment. In specific patient cohorts, treatment strategies may involve a combination of neuroleptics and antiepileptics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the FDA-approved drugs for schizophrenia @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for&nbsp;Schizophrenia Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Therapies and Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Brexpiprazole: Otsuka Pharmaceutical Development &amp; Commercialization, Inc.\/H. Lundbeck A\/S<\/li>\n<li>ICLEPERTIN (BI-425809): Boehringer Ingelheim<\/li>\n<li>KarXT (Xanomeline-Trospium): Karuna Therapeutics<\/li>\n<li>NUPLAZID (pimavanserin): Acadia Pharmaceuticals<\/li>\n<li>MK-5720: Merck<\/li>\n<li>NaBen: SyneuRx International (Taiwan) Corp<\/li>\n<li>Brilaroxazine (RP-5063): Reviva Pharmaceuticals<\/li>\n<li>ULOTARONT (SEP-363856): Sunivion\/PsychoGenics\/Otsuka Pharmaceuticals<\/li>\n<li>LUVADAXISTAT (NBI 1165844\/TAK 831): Neurocrine Biosciences\/Takeda<\/li>\n<li>Roluperidone (MIN-101): Minerva Neurosciences<\/li>\n<li>BXCL501 80: BioXcel Therapeutics Inc<\/li>\n<li>TV-44749: Teva Branded Pharmaceutical Products R&amp;D, Inc.<\/li>\n<li>Evenamide (NW-3509\/NW-3509A): Newron Pharmaceuticals<\/li>\n<li>LYN-005 (risperidone, weekly): Lyndra Therapeutics<\/li>\n<li>OKEDI (risperidone ISM): Pharmaceuticals Laboratories<\/li>\n<li>Emraclidine (CVL-231): Cerevel Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about schizophrenia clinical trials, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Schizophrenia Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Schizophrenia Market Dynamics<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of schizophrenia are anticipated to change in the coming years. The rising trend in the&nbsp;<strong>adoption of long-acting injectable (LAI) antipsychotic medications<\/strong>&nbsp;is a primary catalyst for the expansion of the global market for schizophrenia drugs. The World Health Organization&rsquo;s Comprehensive Mental Health Action Plan for the period 2013-2030 is set to contribute significantly to promoting&nbsp;<strong>mental health awareness<\/strong>&nbsp;and facilitating access to high-quality and affordable care for mental health disorders, aiming to reach an additional&nbsp;<strong>100 million people<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Schizophrenia&nbsp;Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Therapeutic Assessment:&nbsp;Schizophrenia current marketed and emerging therapies<\/li>\n<li>Schizophrenia&nbsp;Market Dynamics:&nbsp;Attribute Analysis of Emerging Schizophrenia Drugs<\/li>\n<li>Competitive Intelligence Analysis:&nbsp;SWOT analysis and Market entry strategies<\/li>\n<li>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Schizophrenia Market Access and Reimbursement<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about schizophrenia drugs in development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Schizophrenia Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Schizophrenia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Executive Summary of Schizophrenia<\/p>\n<p style=\"text-align: justify;\">5. Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">6. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Patient Journey<\/p>\n<p style=\"text-align: justify;\">9. Key Endpoints in Schizophrenia Clinical Trials<\/p>\n<p style=\"text-align: justify;\">10. Marketed Therapies<\/p>\n<p style=\"text-align: justify;\">11. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Conjoint Analysis<\/p>\n<p style=\"text-align: justify;\">13. Schizophrenia: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">15. KOL Views<\/p>\n<p style=\"text-align: justify;\">16. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">17. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Appendix<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-schizophrenia-market-size-is-a-direct-consequence-of-the-increasing-prevalence-of-schizophrenia-among-the-7mm-countries\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/primary-research-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-schizophrenia-market-size-is-a-direct-consequence-of-the-increasing-prevalence-of-schizophrenia-among-the-7mm-countries\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s&nbsp;Schizophrenia Market Insights&nbsp;report includes a comprehensive understanding of current treatment practices, schizophrenia emerging drugs, market share of individual therapies, and current and forecasted schizophrenia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-schizophrenia-market-size-is-a-direct-consequence-of-the-increasing-prevalence-of-schizophrenia-among-the-7mm-countries_691061.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-691061","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/691061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=691061"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/691061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=691061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=691061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=691061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}